Neuropeptide Y

Neuropeptide Y (NPY) is a 36-amino acid peptide amide first isolated from porcine brain by Tatemoto and Mutt in 1982. It belongs to the pancreatic polypeptide family alongside peptide YY (PYY) and pancreatic polypeptide (PP), all sharing a characteristic "PP-fold" tertiary structure mediated by intramolecular interactions between their N-terminal and C-terminal helices. NPY is one of the most abundant and widely distributed neuropeptides in the peripheral and central nervous systems of mammals.

NPY signals through a family of five G-protein-coupled receptors (Y1, Y2, Y4, Y5, and Y6) that differ in their affinity for NPY, PYY, and PP and in their intracellular coupling. All functional NPY receptors couple to Gi proteins to inhibit adenylyl cyclase and reduce cAMP, and many also activate inwardly rectifying potassium channels to hyperpolarise target neurons - making NPY predominantly inhibitory in neural circuits.

The role of NPY as the dominant appetite-stimulating signal in the hypothalamus is well established. NPY is released from neurons in the arcuate nucleus (ARC) that co-express AgRP, and these AGRP/NPY neurons represent the primary "hunger" signalling system in the brain. When energy stores are low (signalled by low leptin, high ghrelin, and low insulin), AGRP/NPY neurons are activated and release NPY into the paraventricular nucleus, lateral hypothalamus, and elsewhere to stimulate food intake, reduce energy expenditure, and increase appetite for energy-dense foods. Blocking NPY signalling reduces food intake; NPY injection into the ARC or PVN produces voracious eating. The magnitude of NPY's orexigenic effect exceeds that of any other known molecule.

The relationship between NPY and stress resilience is a critical and underappreciated aspect of this peptide's biology. Human research conducted primarily with combat veterans has established that plasma NPY levels are significantly higher in elite special operations soldiers compared to non-elite soldiers, and that high NPY levels before deployment predict lower post-traumatic stress symptoms after combat exposure. The proposed mechanism involves NPY-mediated suppression of the locus coeruleus and reduction of stress-responsive noradrenergic tone. NPY gene variants have been associated with PTSD vulnerability in multiple human genetic studies, and NPY replacement in animal models of PTSD reduces anxiety-like behaviour and hyperarousal.

The cardiovascular significance of NPY is substantial and distinct from its CNS roles. NPY is co-stored and co-released with noradrenaline from sympathetic varicosities throughout the body, acting as a post-junctional co-transmitter. At the level of vascular smooth muscle, NPY acts on Y1 receptors to potentiate noradrenaline's vasoconstrictive effect. During periods of intense sympathetic activation (stress, haemorrhage, exercise), plasma NPY levels rise dramatically and contribute to the maintenance of blood pressure. In hypertension, chronically elevated NPY contributes to increased vascular resistance. The Y2 receptor, located presynaptically on sympathetic terminals, provides negative feedback to inhibit further noradrenaline release - a mechanism targeted by Y2 agonists in cardiovascular research.

NPY's anti-seizure properties represent a clinically important but underexplored aspect of its biology. Hippocampal NPY neurons are strongly activated during seizures and serve as an endogenous brake on seizure propagation. Animals with NPY deficiency (NPY knockout mice) show dramatically increased seizure susceptibility, while NPY overexpression reduces seizure frequency in epilepsy models. Several NPY analogues and viral vectors delivering NPY have shown efficacy in reducing seizures in preclinical epilepsy models, and NPY gene therapy is currently in early-phase clinical trials for refractory temporal lobe epilepsy.